Male breast cancer: finding the way in this uncommon path.
Authors : Maurer C, Martel S, de Azambuja E
Year : 2017
Journal : ESMO Open
Volume : 2
Pages : e000169
Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.
Authors : Kourie HR, El Rassy E, Clatot F, de Azambuja E, Lambertini M
Year : 2017
Journal : Onco Targets Ther
Volume : 10
Pages : 3363-3372
Breast cancer treatment-induced cardiotoxicity.
Authors : Martel S, Maurer C, Lambertini M, Pondé N, de Azambuja E
Year : 2017
Journal : Expert Opin Drug Saf
Volume : 16(9)
Pages : 1021-1038
Systemic chemotherapy regimens in early breast cancer patients: updated recommendations from the BSMO breast cancer task force.
Authors : Wildiers H, Duhoux F, Awada A, de Azambuja E
Year : 2017
Journal : Belgian J Medical Oncology
Volume : 11(8)
Pages : 375-379
Phosphoethanolamine and the danger of unproven drugs.
Authors : Pondé N, de Azambuja E, Ades F
Year : 2016
Journal : Ecancermedicalscience
Volume : 10
Pages : 681
I-SPY 2: optimising cancer drug development in the 21st century.
Authors : Bartsch R, de Azambuja E
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000113
Threat posed by unproven drugs in medical oncology.
Authors : Pondé N, Ades F, de Azambuja E
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000064
Twenty years of anti-HER2 therapy-associated cardiotoxicity.
Authors : Pondé NF, Lambertini M, de Azambuja E
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000073
The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.
Authors : Lambertini M, Pinto AC, Ameye L, Jongen L, Del Mastro L, Puglisi F, Poggio F, Bonotto M, Floris G, Van Asten K, Wildiers H, Neven P, de Azambuja E, Paesmans M, Azim HA Jr
Year : 2016
Journal : Br J Cancer
Volume : 115(12)
Pages : 1471-78
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
Authors : Ignatiadis M, Zardavas D, Lemort M, Wilke C, Vanderbeeken MC, Dhondt V, de Azambuja E, Gombos A, Lebrun F, Dal Lago L, Bustin F, Maetens M, Ameye L, Veys I, Michiels S, Paesmans M, Larsimont D, Sotiriou C, Nogaret JM, Piccart-Gebhart M, Awada A
Year : 2016
Journal : PLoS One
Volume : 11(7)
Pages : e0154009
Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).
Authors : Morgan G, Lambertini M, Kourie HR, Amaral T, Argiles G, Banerjee S, Cardone C, Corral J, De Mattos-Arruda L, Öztürk A, Petrova M, Poulsen L, Strijbos M, Tyulyandina A, Vidra R, Califano R, de Azambuja E, Garrido Lopez P, Guarneri V, Reck M, Moiseyenko V, Martinelli E, Douillard JY, Stahel R, Voest E, Arnold D, Cardoso F, Casali P, Cervantes A, Eggermont AM, Eniu A, Jassem J, Pentheroudakis G, Peters S, McGregor K, Rauh S, Zielinski CC, Ciardiello F, Tabernero J, Preusser M
Year : 2016
Journal : ESMO Open
Volume : 1
Pages : e000107
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Authors : Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart-Gebhart M, Azim HA Jr
Year : 2016
Journal : J Natl Cancer Inst
Volume : 108
Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.
Authors : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Year : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pages : 1040-7
The current use and attitudes towards tumor genome sequencing in breast cancer.
Authors : Gingras I, Sonnenblick A, de Azambuja E, Paesmans M, Delaloge S, Aftimos P, Piccart-Gebhart M, Sotiriou C, Ignatiadis M, Azim HA Jr
Year : 2016
Journal : Sci Rep
Volume : 6
Pages : 22517
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience.
Authors : Metzger-Filho O, de Azambuja E, Procter M, Krieguer M, Smith I, Baselga J, Cameron D, Untch M, Jackisch C, Bell R, Gianni L, Goldhirsch A, Piccart-Gebhart M, Gelber Rd
Year : 2016
Journal : Breast Cancer Res Treat
Volume : 155
Pages : 127-32
Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries.
Authors : Antoine C, Ameye L, Paesmans M, de Azambuja E, Rozenberg S
Year : 2016
Journal : Maturitas
Volume : 84
Pages : 81-8
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.
Authors : Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, Zujewski JA, Goldhirsch A, Armour A, Pritchard KI, McCullough AE, Dolci S, Mcfadden E, Holmes AP, Tonghua L, Eidtmann H, Dinh P, Di Cosimo S, Harbeck N, Tjulandin S, Im YH, Huang CS, Diéras V, Hillman DW, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Suter T, Gelber Rd, Perez EA
Year : 2016
Journal : J Clin Oncol
Volume : 34(10)
Pages : 1034-42
Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer.
Authors : Palmieri C, Macpherson IR, Yan K, Ades F, Riddle P, Ahmed R, Owadally W, Stanley B, Shah D, Gojis O, Januszewski A, Lewanski C, Asher R, Lythgoe D, de Azambuja E, Beresford M, Howell SJ
Year : 2016
Journal : Oncotarget
Volume : 7(11)
Pages : 13209-20
Cardiac assessment of early breast cancer patients 18years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
Authors : de Azambuja E, Ameye L, Diaz M, Vandenbossche S, Aftimos P, Hernández SB, Shih-Li C, Delhaye F, Focan C, Cornez N, Vindevoghel A, Beauduin M, Lemort M, Paesmans M, Suter T, Piccart-Gebhart M
Year : 2015
Journal : Eur J Cancer
Volume : 51
Pages : 2517-24
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.
Authors : Sonnenblick A, Francis PA, Azim HA, de Azambuja E, Nordenskjöld B, Gutiérez J, Quinaux E, Mastropasqua MG, Ameye L, Anderson M, Lluch A, Gnant M, Goldhirsch A, Di Leo A, Barnadas A, Cortes-Funes H, Piccart-Gebhart M, Crown J
Year : 2015
Journal : Eur. J. Cancer
Volume : 51(12)
Pages : 1481-9